Articles
6
All (6)
SCI-E, SSCI, AHCI (4)
SCI-E, SSCI, AHCI, ESCI (4)
Scopus (4)
Other Publications (2)
5. HOW IS THE EFFICACY OF PATIENT SELECTION CRITERIA FOR ADJUVANT PEMBROLIZUMAB AFTER CURATIVE SURGICAL TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA WITH INTERMEDIATE TO HIGH RISK OF RECURRENCE? A REAL-LIFE DATA ANALYSIS FROM SINGLE INSTITUTIONAL EXPERIENCE
THE JOURNAL OF UROLOGY
, vol.211,5, pp.436-437, 2024 (Conference Book)
Papers Presented at Peer-Reviewed Scientific Conferences
24
1. Radikal sistektomi uygulanan hastalarda vücut kitle indeksi ve preoperatif albümin değeri ile postoperatif hastanede yatış süresi ve ciddi komplikasyon gelişimi arasındaki ilişki
IURES 2025 Kongresi, Muğla, Turkey, 6 - 09 November 2025, pp.27-29, (Summary Text)
2. Kasa invaze mesane kanseri tanılı hastalarda neoadjuvan kemoterapinin genel sağkalım ve kansere özgü sağkalım üzerine etkileri
IURES 2025 Kongresi, Muğla, Turkey, 6 - 09 November 2025, pp.37-39, (Summary Text)
3. How is the efficacy of patient selection criteria for adjuvant pembrolizumab after curative surgery of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience
IURES 2025 Kongresi, Muğla, Turkey, 6 - 09 November 2025, pp.28-30, (Summary Text)
4. Üreter Anomalisi Olan Bir Hastada Üriner Sistem Tüberküloz Olgusu
IURES 2025 Kongresi, Muğla, Turkey, 6 - 09 November 2025, pp.35-36, (Summary Text)
5. Radikal Sistektomi uygulanan kasa invaze mesane kanseri tanılı hastalarda preoperatif Nötrofil/Lenfosit oranı organa sınırlı hastalığı öngörebilir mi?
IURES 2025 Kongresi , Muğla, Turkey, 6 - 09 November 2025, pp.35-36, (Summary Text)
6. Robotik Cerrahilerde Anestezi Deneyimimiz: Pulmoner, Kardiyovasküler ve Renal Sistem Üzerine Etkileri
IURES 2025 Kongresi, Muğla, Turkey, 6 - 09 November 2025, pp.29-32, (Summary Text)
11. How is the efficacy of patient selection criteria for adjuvant pembrolizumab after curative surgical treatment of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience
16th European Multidisciplinary Congress on Urological Cancers (EMUC) 2024, Lizbon, Portugal, 7 - 10 November 2024, pp.262-263, (Full Text)
15. How Is The Effıcacy Of Patıent Selectıon Crıterıa For Adjuvant Pembrolızumab After Curatıve Surgıcal Treatment Of Clear Cell Renal Cell Carcınoma Wıth Intermedıate To Hıgh Rısk Of Recurrence? A Real-Lıfe Data Analysıs From Sıngle Instıtutıonal Experıence
American Urological Association's 2024 Annual Meeting, San-Antonio, Northern Mariana Islands, 3 - 06 May 2024, pp.436-437, (Full Text)